Abstract
We describe the case of a patient with a diagnosis of Crohn’s disease and accidental infection during abdominal surgery by hepatitis C virus (HCV) who received combination therapy with pegylated interferon-α2b (1.5 µg/kg weekly) plus ribavirin (10.6 mg/kg daily) for histologically demonstrated chronic hepatitis C. After 48 weeks treatment, serum transaminase levels were normal and viremia (HCV RNA) was negative (end-of-treatment response); 24 weeks later (follow-up period), a sustained virological response was demonstrated. The tolerance to combination antiviral therapy was good, without intestinal symptoms of inflammatory bowel disease recurrence. We conclude that current antiviral therapies with immunomodulatory effects may be helpful and safe for patients with inflammatory bowel disease infected by hepatitis C virus.
Journal Section:
Case Report
References
1.
Afdhal NH: The natural history of hepatitis C. Semin Liver Dis 2004;24:3–8.
[PubMed]
2.
Busch MP, Kleinman SH, Nemo GJ: Current and emerging infectious risks of blood transfusion hepatitis. JAMA 2003;289:959–963.
[PubMed]
3.
Leone N, Rizzetto M: Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Min Gastroenterol Dietol 2005;51: 31–46.
[PubMed]
4.
Dickson RC: Clinical manifestations of hepatitis C. Clin Liver Dis 1997;1:569–585.
[PubMed]
5.
Artor RB: Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol Clin N Am 1995;24:475–507.
[PubMed]
6.
Longo F, Hebuterne X, Tran A, Staccini P: Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol 2000;24:77–81.
[PubMed]
7.
Medina J, Garcia-Buey L, Moreno-Monteagudo JA, Trapero-Marugan M, Moreno-Otero R: Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res 2003;60:135–143.
[PubMed]
8.
Shepard CW, Finelli L, Alter M: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558–566.
[PubMed]
9.
MacDermott RP: Chemokines in the inflammatory bowel diseases. J Clin Immunol 1999;19:266–272.
[PubMed]
10.
Wen Z, Fiocchi C: Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 2004;11:195–204.
[PubMed]
11.
Chang K: Immunopathogenesis of hepatitis C virus infection (Review). Clin Liver Dis 2003;7: 89–105.
[PubMed]
12.
Rehermann B: Interaction between the hepatitis C virus and the immune system. Semin Liver Dis 2000;20:127–141.
[PubMed]
13.
Tilg H: New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017–1021.
[PubMed]
14.
Gutterman JU: Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994;91:1198–1205.
[PubMed]
15.
Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002;347:417–429.
[PubMed]
16.
Bargiggia S, Thorburn D, Anderloni A, Ardizzone S, Giorgi A, Bianchi Porro G, Parente F: Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther 2005;22:209–215.
[PubMed]
17.
Mitoro A, Yoshikawa M, Yamamoto K, Mimura M, Yoshikawa Y, Shiroi A, Mochi T, Sakamoto T, Yamao J, Kikuchi E, H Fukui H, Tsuji T: Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C. Intern Med 1993;32:327–331.
[PubMed]
18.
Legaz ML, Arteaza T, Alcantatra M, Sanchez JJ, Lopez I, Martinez JL: Recombinant alfa-2 interferon treatment of a patient with chronic hepatitis B and ulcerative colitis. Gastroenterol Hepatol 1996;19:55–57.
[PubMed]
19.
De Diego Lorenzo A, Kashoob M, Romero M, Parera A, Duran F, Piqueras B, Santos L, Cos E, Clemente G: Treatment with recombinant interferon alfa-2b of a patient with chronic hepatitis C and concomitant ulcerative colitis. Rev Esp Enferm Dig 1997;89:399–401.
[PubMed]
20.
Cottone M, Magliocco A, Trallori G, Brignola C, Vandelli C, Ardizzone S, Meucci G, Zannoni F, Di Maio G, Astegiano M: Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis. Ital J Gastroenterol 1995;27:3–4.
[PubMed]
21.
Khalil A, Lucidarme D, Desurmont P, Hamdan-Khalil R, Filoche B: Crohn’s disease associated with interferon and ribavirin treatment for chronic hepatitis C. Gastroenterol Clin Biol 2005;29:193–196.
[PubMed]
22.
Castro F, Santaella M, Torres EA, Rodriguez-Medina JR, Gonzalez-Keelan CC: Sustained response to interferon in a patient with common variable immunodeficiency and hepatitis C. Am J Gastroenterol 1997;92:1557–1558.
[PubMed]
© 2006 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2006
You do not currently have access to this content.
